Skip to main content

Algernon Pharmaceuticalsinc(AGN-CN)
CSE

Today's Change
Delayed Last Update
Day Low0.0750
Day High0.0900
Open:0.0900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
GlobeNewswire
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
GlobeNewswire
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
GlobeNewswire
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
GlobeNewswire
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
GlobeNewswire
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
GlobeNewswire
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
ACCESSWIRE
The Power Play by The Market Herald Releases a New Interview with Algernon Pharmaceuticals Discussing Their Latest News
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Algernon, Permex Petroleum, Infinity Stone, Green River Gold, HIRE Technologies, and Aton Resources Discussing Their Latest News
Globe Newswire
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
AccessWire
The Power Play by The Market Herald Releases New Interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals
Globe Newswire
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
AccessWire
The Power Play by The Market Herald Releases New Interviews with K9 Gold, Algernon Pharmaceuticals, Deep-South Resources, and Saturn Oil & Gas
Globe Newswire
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
Globe Newswire
Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
Globe Newswire
Algernon Pharmaceuticals Announces Closing of Public Offering of Units
Globe Newswire
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units
Globe Newswire
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
Globe Newswire
Algernon Pharmaceuticals Announces Public Offering of Units
Globe Newswire
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
AccessWire
The Power Play by The Market Herald Releases New Interviews With Algernon Pharmaceuticals, Adastra Holdings and C3 Metals
Globe Newswire
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
Globe Newswire
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Globe Newswire
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
AccessWire
The Power Play by The Market Herald Releases Interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining
Globe Newswire
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
AccessWire
The Power Play by The Market Herald Releases Interviews With Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals
Globe Newswire
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
AccessWire
The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical
Globe Newswire
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Baystreet
Stocks in play: Algernon Pharmaceuticals Inc
Globe Newswire
Algernon Pharmaceuticals Issues Compensation Options

Profile

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.